RAJENDRA GAJULA: Open Payments
NPI 1124011614 · DALLAS, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,965 in 51 payments from 12 companies in 2025. Trend: 2023 $7,715 · 2024 $1,611 · 2025 $1,965
Food & beverage: $1,886Education: $80
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $489 |
| Teva Pharmaceuticals USA, Inc. | 10 | $405 |
| E.R. Squibb & Sons, L.L.C. | 8 | $343 |
| Janssen Pharmaceuticals, Inc | 3 | $215 |
| JAZZ PHARMACEUTICALS INC. | 1 | $123 |
| Biogen, Inc. | 1 | $120 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $110 |
| Vanda Pharmaceuticals Inc. | 2 | $63 |
| ABBVIE INC. | 2 | $41 |
| Indivior Inc. | 1 | $24 |
Products named: COBENFY, ABILIFY MAINTENA, INVEGA SUSTENNA, UZEDY, REXULTI, AUSTEDO XR, XYWAV, ZURZUVAE.
Industry payments across PA — which companies pay providers there.
